Reactivation of Chagas’ disease in a patient with non-Hodgkin's lymphoma: gastric, oesophageal and laryngeal involvement

Rezende, Rosamar Eulira Fontes; Lescano, Manuel; Ramalho, Leandra Náira Zambelli; Figueiredo, José Fernando de Castro; Dantas, Roberto Oliveira; Meneghelli, U. G.; Modena, José Luiz Pimenta

doi:10.1016/j.trstmh.2005.07.005

Cited by 26 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This may occur inadvertently, in cases in which the patient undergoes transplantation without knowing that he/she has Chagas disease (usually in asymptomatic individuals in non-endemic countries), or due to heart transplant as a result of Chagas-related cardiac damage. Recent studies have shown that recurrence of Chagas disease may also occur in patients with lymphoreticular neoplasias, especially acute lymphocytic leukemia or Hodgkin's disease [30]. One challenge of identifying Chagas disease in immunosuppressed patients is that sera conversion may not occur.…”

Section: Acute Chagas Disease In Immunocompromised Patients: Importanmentioning

confidence: 99%

Acute Chagas Disease: New Global Challenges for an Old Neglected Disease

2014

View full text Add to dashboard Cite

Chagas disease is caused by infection with the protozoan Trypanosoma cruzi, and although over 100 years have passed since the discovery of Chagas disease, it still presents an increasing problem for global public health. A plethora of information concerning the chronic phase of human Chagas disease, particularly the severe cardiac form, is available in the literature. However, information concerning events during the acute phase of the disease is scarce. In this review, we will discuss (1) the current status of acute Chagas disease cases globally, (2) the immunological findings related to the acute phase and their possible influence in disease outcome, and (3) reactivation of Chagas disease in immunocompromised individuals, a key point for transplantation and HIV infection management.

show abstract

Section: Acute Chagas Disease In Immunocompromised Patients: Importanmentioning

confidence: 99%

Acute Chagas Disease: New Global Challenges for an Old Neglected Disease

2014

View full text Add to dashboard Cite

show abstract

“…Even prior to the advent of the HIV/AIDS pandemic, reactivation of T. cruzi infection had been observed in patients undergoing immunosuppressive therapy for malignancies and organ transplantation [94–97]. Del Castillo et al [98] initially described a 19-year old man with hemophilia who had a hypodense lesion in the right frontal lobe.…”

Section: Chagas Disease and Immunosuppressionmentioning

confidence: 99%

Perspectives on Trypanosoma cruzi–Induced Heart Disease (Chagas Disease)

Tanowitz

Machado

Jelicks

et al. 2009

Progress in Cardiovascular Diseases

146

145

View full text Add to dashboard Cite

Chagas disease is caused by the parasite Trypanosoma cruzi it is the most common cause of heart disease in endemic areas of Latin America. The year 2009 marks the 100th anniversary of the discovery of T. cruzi infection and Chagas disease by the Brazilian physician Carlos Chagas. Chagasic cardiomyopathy develops in from 10 to 30 percent of persons who are chronically infected with this parasite. Echocardiography and magnetic resonance imaging are important modalities in the evaluation and prognosis of individuals with chagasic heart disease. The etiology of chagasic heart disease likely is multifactorial. Parasite persistence, autoimmunity, and microvascular abnormalities have been studied extensively as possible pathogenic mechanisms. Experimental studies suggest that alterations in cardiac gap junctions may be etiologic in the pathogenesis of conduction abnormalities. The diagnosis of chronic Chagas disease is made by serology. The treatment of this infection has shortcomings that need to be addressed. Cardiac transplantation and bone marrow stem cell therapy for persons with Chagas disease have received increasing research attention in recent years.

show abstract

“…1 Amplamente distribuída pelo continente americano acomete ao redor de 11 milhões de pessoas, com 3-5 milhões de infectados no Brasil. [1][2][3][4] A sua reativação em casos de imunossupressão grave tem sido amplamente demonstrada. 3,[5][6][7][8][9] Os relatos de reativação da DC em pacientes com neoplasias hematológicas comumente associam-se ao transplante de células-tronco hematopoéticas (TCTH) correlacionadas à imunossupressão devido à doença de base, terapia antitu-moral e regimes de condicionamento.…”

Section: Introductionunclassified

“…3,[5][6][7][8][9] Os relatos de reativação da DC em pacientes com neoplasias hematológicas comumente associam-se ao transplante de células-tronco hematopoéticas (TCTH) correlacionadas à imunossupressão devido à doença de base, terapia antitu-moral e regimes de condicionamento. 3 Escassos são os relatos de reativação da doença na vigência de quimioterapia de doença onco-hematológica não associada a TCTH. 3,10,11 O presente caso ilustra reativação da DC com comprometimento de sistema nervoso central em paciente em quimioterapia para linfoma não Hodgkin não relacionado à TCTH, com tardia detecção do parasita em sangue e líquido cefalorraquidiano (LCR) e desfecho fatal a despeito de tratamento.…”

Section: Introductionunclassified

“…3 Escassos são os relatos de reativação da doença na vigência de quimioterapia de doença onco-hematológica não associada a TCTH. 3,10,11 O presente caso ilustra reativação da DC com comprometimento de sistema nervoso central em paciente em quimioterapia para linfoma não Hodgkin não relacionado à TCTH, com tardia detecção do parasita em sangue e líquido cefalorraquidiano (LCR) e desfecho fatal a despeito de tratamento.…”

Section: Introductionunclassified

See 1 more Smart Citation